Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.

Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B

Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.

Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer and Cinven have entered into a definitive agreement regarding the sale of Bayer's Environmental Science Professional business for a purchase price of 2.6 billion U.S. dollars (2.4 billion euros), Bayer announced on Thursday. “This divestment represents a very attractive purchase price and allows us to focus on our core agricultural business and the successful implementation of our Crop Science Division growth strategy,” said Rodrigo Santos, Member of

Bayer to Sell Its Environmental Science Professional Business to Cinven for 2.6 Billion U.S. Dollars

Here is how Bayer Aktiengesellschaft (BAYRY) and AllScripts Healthcare (MDRX) have performed compared to their sector so far this year.

Is Bayer Aktiengesellschaft (BAYRY) Outperforming Other Medical Stocks This Year?

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) as well as the submission of a Variation Type II application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide). Bayer is seeking approval for the use of NUBEQA in combination with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). NUBEQA is curren

Bayer Submits Applications in the U.S. and EU for Additional Indication of NUBEQA® (darolutamide)

SAN FRANCISCO , March 7, 2022 /PRNewswire/ -- The Fears Nachawati law firm is asking a federal judge to reject a proposed settlement between Bayer (OTCMKTS: BAYZF, BAYRY) and its Monsanto subsidiary and a group of consumers seeking reimbursement for their purchases of the Roundup weedkiller, saying the agreement may be the result of collusion designed to limit the ability of cancer victims to obtain justice. In a March 3 filing, Fears Nachawati trial lawyers ask U.S. District Court Judge Vince Chhabria to reject the settlement unless "inherently ambiguous" language is clarified to ensure that the terms do not affect thousands of cancer victims who have sued Monsanto claiming they developed non-Hodgkins lymphoma following exposure to Roundup.

Bayer Monsanto Roundup Cancer Victims Oppose Settlement

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Strengthens Company's Government and Industry Affairs Group in Key U.S. Market with Two Appointments

Bayer Strengthens Company's Government and Industry Affairs Group in Key U.S. Market with Two Appointments

MONHEIM, Germany--(BUSINESS WIRE)--Bayer today announced changes in the leadership team of its Crop Science division, with Kelly Gast assuming the position of Chief Financial Officer (CFO) from Michael A. Schulz, effective April 1, 2022. Schulz had been CFO for the Crop Science division for over a decade and decided to leave Bayer for personal reasons after 16 years with the company. Gast is currently CFO for Bayer's U.S. organization. “Kelly has tremendous experience in finance and a true pass

Bayer Announces Changes in Executive Leadership Team of Crop Science Division

ST. LOUIS--(BUSINESS WIRE)--Bayer announced today the commercial registrations from the EPA for the traits that will enable the commercialization of its newest corn product, VT4PRO™ with RNAi Technology, in the United States. VT4PRO™ Technology* will provide US farmers an additional option within the already-strong Bayer corn product portfolio to help control troublesome above-ground and below ground pests. VT4PRO™ Technology will mark the first product that combines the power of the three mode

Bayer Corn Trait Gains EPA Approval: VT4PRO™ with RNAi Technology to Launch in US as Early as 2024

Werner Enterprises

Bayer AG (BAYZF) CEO Werner Baumann on Q4 2021 Results - Earnings Call Transcript

Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4

German diversified group Bayer said on Tuesday it was aiming for a 7% increase in adjusted core earnings at constant foreign exchange rates this year as an upswing in demand for its seeds and pesticides is partly offset by investments in new genetic treatment technologies.

Bayer predicts full-year profit growth on demand from farmers

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer announced today the advancement of key innovation projects that showcase the latest in crop protection, seeds & traits and digital solutions. These significant advancements, plus more than 500 seed deployments and greater than 300 new crop protection product registrations in 2021 are expected to fuel both mid-and-long-term growth for the company as they bring new value to growers around the globe. The company's new solutions for agriculture are ge

Bayer Highlights Advancements of Agriculture Industry's Most Prolific R&D Pipeline

BASF SE

Corteva Inc

Demand for fresh water is outrunning supply as the result of aquifer and reservoir depletion; farmers are having to cut back. At the same time, crops are coming under stress as the result of climate change / global warming and sustained droughts.

Seeds - The Big Three

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke. Asundexian is an oral inhibitor of Factor Eleven (FXIa) 1 that Bayer is developing as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke as well as for tw

Bayer Receives FDA Fast Track Designation for asundexian Stroke Program

WHIPPANY, N.J.--(BUSINESS WIRE)--For the fifth consecutive year, Bayer U.S. has obtained a perfect score of 100 on the Human Rights Campaign Foundation's 2022 Corporate Equality Index (CEI). The CEI is the nation's foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality. “As we continue to build an inclusive, world-class culture and organization, we are immensely proud to earn this important distinction for a fifth consecutive year

Bayer Earns Top Score in 2022 Corporate Equality Index for Fifth Consecutive Year

CAMBRIDGE, Mass. & LEVERKUSEN, Germany--(BUSINESS WIRE)-- #SeriesA--Leaps by Bayer leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing

Leaps by Bayer Leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing

Bayer AG: Betting On Volatility Expansion

Exclusive agreement with Bayer to evaluate MustGrow's technologies to determine commercial potential.Bayer has the option to acquire exclusive rights to MustGrow's technologies for preplant soil fumigation, bioherbicide applications and postharvest food preservation of potatoes including sprout inhibition in the regions of Europe, Asia Pacific, Middle East and Africa. Bayer will fund and drive all laboratory, field development, regulatory work and market development.Saskatoon, Saskatchewan--(Newsfile Corp. - January 21, 2022) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB:...

MustGrow and Bayer sign Exclusive Agreement to Develop Sustainable Organic Biologicals in Europe, Asia Pacific, Middle East and Africa

BERLIN & BRISBANE, Calif.--(BUSINESS WIRE)-- #Bayer--Mammoth Biosciences partners with Bayer to develop gene-editing therapies for five in vivo indications, first focusing on liver-targeted diseases.

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology

Investors are set to demand around 2.2 billion euros ($2.5 billion) from Bayer as part of a possible class action lawsuit in Germany over the takeover of U.S. seed manufacturer Monsanto, WirtschaftsWoche reported on Monday.

Investors want $2.5 billion in class action over Bayer's Monsanto deal-report

Bayer faces a billion-dollar investor class action lawsuit in Germany over the takeover of U.S. seed manufacturer Monsanto, specialist law firm Tilp Rechtsanwaltsgesellschaft said on Wednesday.

Bayer faces class action suit over Monsanto takeover in Germany, law firm says

The U.S. Supreme Court on Monday asked President Joe Biden's administration for its views on whether the justices should hear Bayer AG's bid to dismiss claims by customers who contend its Roundup weedkiller causes cancer, as the company seeks to avoid potentially billions of dollars in damages.

Supreme Court asks U.S. government for views on Bayer weedkiller case

A California jury found that Bayer's Roundup weedkiller was not the cause of a woman's non-Hodgkin's lymphoma, Bayer said on Thursday, delivering the chemical giant its second trial victory over claims the popular herbicide causes cancer.

Bayer wins second straight verdict in a Roundup cancer case

MONHEIM, Germany--(BUSINESS WIRE)--Today, Bayer, Bushel and Amazon Web Services (AWS) unveiled Project Carbonview. This has been conceptualized by Bayer Crop Science and developed in collaboration with Bushel and AWS. It is a first-of-its-kind technology solution that will help farmers in the United States drive more sustainable supply chains and mitigate the impact agriculture has on the environment by aggregating the carbon footprint of end products. Project Carbonview is the latest example o

News for Bayer AG Stock (BAYRY)